Alibaba Health posts pharmaceutical direct sales revenue of RMB14.4 billion, up 18.6 percent year-on-year for the reporting period ending September 30, 2025

Alibaba Health reported revenue of CNY 16.7 billion for the six months ended September 30, 2025, representing a 17.0% increase from the same period last year. Gross profit grew by 18.4% to CNY 4.2 billion, with the gross profit margin rising to 25.1%. Fulfillment expenses reached CNY 1.4 billion, up 7.9%, while selling and marketing expenses rose 21.2% to CNY 1.2 billion. Administrative expenses totaled CNY 190.1 million, a 3.9% increase, and product development expenses were CNY 313.1 million, down 1.9% for the period. Pharmaceutical direct sales business revenue amounted to CNY 14.4 billion, up 18.6% year-on-year, and platform business revenue was CNY 1.8 billion, up 7.5%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alibaba Health Information Technology Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251211-11952164), on December 11, 2025, and is solely responsible for the information contained therein.